6/19/2026

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Suliqua

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
1 1
1 1

Insuliner

Insuliner

Klass : 1

Visa all info

Skriv ut

Kontakta oss

  1. Aberg A, Westbom L, Källén B et al. Congenital malformations among infants whose mothers had gestational diabetes or preexisting diabetes. Early Hum Dev 2001;61:85-95.

  2. Greene MF, Hare JW, Cloherty JP et al. First-trimester hemoglobin A1 and risk for major malformation and spontaneous abortion in diabetic pregnancy. Teratology 1989;39:225-31.

  3. Steel JM, Johnstone FD, Hepburn DA et al. Can prepregnancy care of diabetic women reduce the risk of abnormal babies? BMJ 1990;301:1070-4.

  4. Wang H, Wender-Ozegowska E, Garne E, Morgan M, Loane M, Morris JK et al. Insulin analogues use in pregnancy among women with pregestational diabetes mellitus and risk of congenital anomaly: a retrospective population-based cohort study. BMJ Open. 2018;8:e014972.

  5. Toledano Y, Hadar E, Hod M. Safety of insulin analogues as compared with human insulin in pregnancy. Expert Opin Drug Saf. 2016;15:963-73.

  6. Mathiesen ER, Ali N, Alibegovic AC, Anastasiou E, Cypryk K, de Valk H et al. Risk of Major Congenital Malformations or Perinatal or Neonatal Death With Insulin Detemir Versus Other Basal Insulins in Pregnant Women With Preexisting Diabetes: The Real-World EVOLVE Study. Diabetes Care. 2021;44(9):2069-2077.

  1. Aberg A, Westbom L, Källén B et al. Congenital malformations among infants whose mothers had gestational diabetes or preexisting diabetes. Early Hum Dev 2001;61:85-95.
  2. Greene MF, Hare JW, Cloherty JP et al. First-trimester hemoglobin A1 and risk for major malformation and spontaneous abortion in diabetic pregnancy. Teratology 1989;39:225-31.
  3. Steel JM, Johnstone FD, Hepburn DA et al. Can prepregnancy care of diabetic women reduce the risk of abnormal babies? BMJ 1990;301:1070-4.
  4. Wang H, Wender-Ozegowska E, Garne E, Morgan M, Loane M, Morris JK et al. Insulin analogues use in pregnancy among women with pregestational diabetes mellitus and risk of congenital anomaly: a retrospective population-based cohort study. BMJ Open. 2018;8:e014972.
  5. Toledano Y, Hadar E, Hod M. Safety of insulin analogues as compared with human insulin in pregnancy. Expert Opin Drug Saf. 2016;15:963-73.
  6. Mathiesen ER, Ali N, Alibegovic AC, Anastasiou E, Cypryk K, de Valk H et al. Risk of Major Congenital Malformations or Perinatal or Neonatal Death With Insulin Detemir Versus Other Basal Insulins in Pregnant Women With Preexisting Diabetes: The Real-World EVOLVE Study. Diabetes Care. 2021;44(9):2069-2077.
2 2
2 2

Lixisenatid

Lixisenatid

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Kettner J, Donnelly E, Maes ML. Glucagon-like Peptide-1 Receptor Agonists and Reproductive Health: Current Evidence and Clinical Implications. J Pharm Pract. 2026 6;39(3):239-250.

  2. Armstrong BBS, Servidoni ACP, Martin GCC, Machado GF, Amador WFO, Yousif A. Evaluation of GLP-1 receptor agonists in obstetrics and perinatal outcomes: A systematic review and meta-analysis. J Gynecol Obstet Hum Reprod. 2025 12;54(10)

  3. Dao K, Shechtman S, Weber-Schoendorfer C, Diav-Citrin O, Murad RH, Berlin M, Hazan A, Richardson JL, Eleftheriou G, Rousson V, Diezi L, Haefliger D, Simões-Wüst AP, Addor MC, Baud D, Lamine F, Panchaud A, Buclin T, Girardin FR, Winterfeld U. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open. 2024 4;14(4)

  4. Chou YC, Weng SH, Cheng FS, Tseng CH, Hu HY, Liu CH. Unintentional periconceptional exposure to glucagon-like peptide-1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan. Diabetes Obes Metab. 2026 2;28(2):1420-1430.

  5. Cesta CE, Rotem R, Bateman BT, Chodick G, Cohen JM, Furu K, Gissler M, Huybrechts KF, Kjerpeseth LJ, Leinonen MK, Pazzagli L, Zoega H, Seely EW, Patorno E, Hernández-Díaz S. Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. JAMA Intern Med. 2024 2 1;184(2):144-152.

  6. Parker CH, Slattery C, Brennan DJ, le Roux CW. Glucagon-like peptide 1 (GLP-1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials. Diabetes Obes Metab. 2025 8;27(8):4102-4108.

  7. Brown JP, Huybrechts KF, Straub L, Patorno E, Seely EW, Bateman BT, Hernández-Díaz S. Continuing Glucagon-Like Peptide-1 Receptor Agonists Into the First Trimester of Pregnancy and Pregnancy Outcomes : A Target Trial Emulation Study Using Claims Information. Ann Intern Med. 2026 June 9.

  8. Cesta CE, Hutcheon JA, Johansson K. Guiding Obstetric Care and Treatment Decisions for Women With Prior GLP-1 Receptor Agonist Use. JAMA. 2025 12 23;334(24):2168-2170.

  9. Sanofi AB. Suliqua. Produktresumé. EMA [www]. [updated 2024-10-25, cited 2026-06-01].

  1. Kettner J, Donnelly E, Maes ML. Glucagon-like Peptide-1 Receptor Agonists and Reproductive Health: Current Evidence and Clinical Implications. J Pharm Pract. 2026 6;39(3):239-250.
  2. Armstrong BBS, Servidoni ACP, Martin GCC, Machado GF, Amador WFO, Yousif A. Evaluation of GLP-1 receptor agonists in obstetrics and perinatal outcomes: A systematic review and meta-analysis. J Gynecol Obstet Hum Reprod. 2025 12;54(10)
  3. Dao K, Shechtman S, Weber-Schoendorfer C, Diav-Citrin O, Murad RH, Berlin M, Hazan A, Richardson JL, Eleftheriou G, Rousson V, Diezi L, Haefliger D, Simões-Wüst AP, Addor MC, Baud D, Lamine F, Panchaud A, Buclin T, Girardin FR, Winterfeld U. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open. 2024 4;14(4)
  4. Chou YC, Weng SH, Cheng FS, Tseng CH, Hu HY, Liu CH. Unintentional periconceptional exposure to glucagon-like peptide-1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan. Diabetes Obes Metab. 2026 2;28(2):1420-1430.
  5. Cesta CE, Rotem R, Bateman BT, Chodick G, Cohen JM, Furu K, Gissler M, Huybrechts KF, Kjerpeseth LJ, Leinonen MK, Pazzagli L, Zoega H, Seely EW, Patorno E, Hernández-Díaz S. Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. JAMA Intern Med. 2024 2 1;184(2):144-152.
  6. Parker CH, Slattery C, Brennan DJ, le Roux CW. Glucagon-like peptide 1 (GLP-1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials. Diabetes Obes Metab. 2025 8;27(8):4102-4108.
  7. Brown JP, Huybrechts KF, Straub L, Patorno E, Seely EW, Bateman BT, Hernández-Díaz S. Continuing Glucagon-Like Peptide-1 Receptor Agonists Into the First Trimester of Pregnancy and Pregnancy Outcomes : A Target Trial Emulation Study Using Claims Information. Ann Intern Med. 2026 June 9.
  8. Cesta CE, Hutcheon JA, Johansson K. Guiding Obstetric Care and Treatment Decisions for Women With Prior GLP-1 Receptor Agonist Use. JAMA. 2025 12 23;334(24):2168-2170.
  9. Sanofi AB. Suliqua. Produktresumé. EMA [www]. [updated 2024-10-25, cited 2026-06-01].